Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03114917
Other study ID # 13/161/25
Secondary ID 220
Status Completed
Phase N/A
First received
Last updated
Start date May 12, 2017
Est. completion date January 27, 2022

Study information

Verified date May 2023
Source University of Manchester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomised controlled trial which investigates the effectiveness of CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy in reducing suicidal thoughts and how well CARMS works in practice within the NHS. The trial will compare two groups of people with psychosis who are using NHS mental health services. One group will carry on with their usual treatment. The other group will be offered 24 weekly sessions of CARMS therapy, plus their usual treatment.


Description:

Estimates show that around 6% of people with experiences of psychosis die by suicide. Many more think about it and attempt suicide. A meta-analysis by the investigators illustrated that psychological therapies are effective in reducing suicidal thoughts and acts in people with psychosis as long as those therapies target suicidal thoughts, intentions and plans, and not the reduction of symptoms of mental illnesses. Based on this work, we have designed a psychological cognitive "talking" therapy (called CARMS) to reduce suicidal thoughts in people with experiences of psychosis which targets the psychological processes thought to underpin the pathways to suicidal thoughts and behaviours. An increasing body of work shows that many people with psychosis experience social isolation, emotional dysregulation, and poor interpersonal problem-solving. These appraisals can then induce and intensify perceptions of being hopeless, trapped and defeated, which in turn leads to suicidal thoughts and acts. CARMS aims to help people find practical ways to change these sorts of perceptions. Two of the investigators' pilot randomised trials have demonstrated that CARMS is feasible and acceptable to people experiencing psychosis and may have the potential to be effective at reducing key suicide outcomes. Hence, the investigators' next step is to test the efficacy of CARMS in the context of NHS mental health services and also to test whether the underlying psychological mechanisms on which CARMS is based are correct. The investigators will test CARMS using a medium sized randomised controlled trial (RCT), with two arms of CARMS plus treatment as usual versus just treatment as usual. The target sample size is 250, with approximately 125 randomised to each arm of the trial, and an assumption of up to 25% attrition. Hence, the overall recruitment target is up to 333. The investigators will use both quantitative and qualitative methods and analyses to assess CARMS.


Recruitment information / eligibility

Status Completed
Enrollment 329
Est. completion date January 27, 2022
Est. primary completion date January 27, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ICD-10 diagnosis of psychosis (i.e. F20 - F29) - suicidal thoughts and/or acts in the past three months - in contact with mental health services and under the care of a mental health services clinical team (i.e., community or inpatient mental health care teams) with a care coordinator - aged 18 or over - English-speaking (hence, not needing an interpreter) - able to give informed consent as assessed by either a responsible clinician or by trial RAs following the British Psychological Society's guidelines on gaining informed consent (http://www.bps.org.uk/sites/default/files/documents/code_of_human_research_ethics.pdf ) Exclusion Criteria: - dementia, or an organic brain disorder - unable to complete assessments due to language barriers - currently taking part in a clinical trial.

Study Design


Intervention

Other:
Cognitive AppRoaches to coMbatting Suicidality (CARMS)
The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.

Locations

Country Name City State
United Kingdom Pennine Care NHS Foundation Trust Ashton under Lyne
United Kingdom Lancashire Care NHS Foundation Trust Chorley
United Kingdom Greater Manchester Mental Health NHS Trust Manchester
United Kingdom Northwest Boroughs Healthcare NHS Foundation Trust Warrington

Sponsors (3)

Lead Sponsor Collaborator
University of Manchester Greater Manchester Mental Health NHS Foundation Trust, Lancaster University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from Baseline Difficulties in Emotional Regulation Scale score at 6 and 12 months The questionnaire measures emotional dysregulation Baseline, 6 month and 12 month follow up
Other Change from Baseline Social Problem-Solving Inventory score at 6 and 12 months The questionnaire measures individual's social problem-solving skills Baseline, 6 month and 12 month follow up
Other Change from Baseline Social Support Appraisals Scale score at 6 and 12 months The questionnaire measures individual's appraisals of social support Baseline, 6 month and 12 month follow up
Other Change from Baseline Beck Hopelessness Scale score at 6 and 12 months The questionnaire measures three aspects of hopelessness: feelings about the future, loss of motivation, and expectations Baseline, 6 month and 12 month follow up
Other Change from Baseline Defeat and Entrapment scale scores at 6 and 12 months The questionnaire measures how defeated and trapped individuals feel respectively Baseline, 6 month and 12 month follow up
Other Change from Baseline Positive and Negative Syndrome Scale score at 6 and 12 months Clinical interview to assess symptom severity of individual's experiencing Schizophrenia Baseline, 6 month and 12 month follow up
Other Change from Baseline Psychotic Symptoms Ratings Scale (PSYRATS) score at 6 and 12 months Clinical interview to assess symptoms of psychosis Baseline, 6 month and 12 month follow up
Other Change from Baseline Personal and Social Performance Scale score at 6 and 12 months Clinical interview to assess personal and social functioning in individual's experiencing Schizophrenia Baseline, 6 month and 12 month follow up
Other Change from Baseline Calgary Depression Scale score at 6 and 12 months Clinical interview to assess symptoms of depression in individual's experiencing Schizophrenia Baseline, 6 month and 12 month follow up
Other Change from Baseline Frequency and Type of Substance Misuse as measured by the Timeline Follow Back at 6 and 12 months Clinical interview to ascertain frequency and type of substance misuse over 3 months Baseline, 6 month and 12 month follow up
Other Change from Baseline Drug use (self-reported) DAST score at 6 and 12 months Measure which identifies drug 'abuse' Baseline, 6 month and 12 month follow up
Other Change from Baseline Alcohol use (self-reported) AUDIT score at 6 and 12 months Gold standard measure which identifies alcohol use Baseline, 6 month and 12 month follow up
Other Change from Baseline Reasons for substance Use Scale - Alcohol and Drugs scores at 6 and 12 months Questionnaire measure which identifies individual's reasons for using alcohol and drugs respectively Baseline, 6 month and 12 month follow up
Other Change from Baseline Sleep Condition Indicator score at 6 and 12 months The questionnaire measures insomnia Baseline, 6 month and 12 month follow up
Other Current medication for mental health problems as prescribed at baseline assessment time point Information regarding which anti-psychotic medication, if the medication is atypical, and the dosage will be collected from medical records Baseline
Other Change from Baseline Working Alliance Inventory - short form score at 6 and 12 months The questionnaire measure the client-therapist therapeutic alliance from the participant's and the therapist's perspective Baseline, 6 month and 12 month follow up
Other Change from Baseline EQ-5D score at 12 months The questionnaire measures health outcomes Baseline and 12 month follow up
Other Change from Baseline Client Service Use Receipt Inventory at 12 months The questionnaire measures use of services Baseline and 12 month follow up
Primary Change from Baseline Adult Suicide Ideation Questionnaire score at 6 and 12 months Suicidal ideation valid measure Baseline, 6 month and 12 month follow up
Secondary Change from Baseline Suicide Probability Scale score at 6 and 12 months Suicide risk valid measure Baseline, 6 month and 12 month follow up
Secondary Change from Baseline Beck Scale for Suicidal ideation score at 6 and 12 months Assess an individual's thoughts, attitudes and intentions regarding suicide Baseline, 6 month and 12 month follow up
Secondary Change from Baseline Frequency of suicidal thoughts, plans and acts at 6 and 12 months Clinical interview to ascertain frequency of suicidal thoughts, plans and acts across six months Baseline, 6 month and 12 month follow up
Secondary Change from Baseline Frequency of Suicide Attempts at 6 and 12 months Frequency of suicide attempts will be collected from medical records Baseline, 6 month and 12 month follow up
See also
  Status Clinical Trial Phase
Recruiting NCT04929938 - Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients N/A
Recruiting NCT05863572 - Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda N/A
Completed NCT04277585 - Improving Access to Early Psychosis Coordinated Specialty Care N/A
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Not yet recruiting NCT05558332 - Youth Nominated Support Team N/A
Not yet recruiting NCT05358457 - Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf) N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Completed NCT02895269 - COllaborative Shared Care to IMprove Psychosis Outcome N/A
Recruiting NCT02622048 - Understanding and Helping Families: Parents With Psychosis N/A
Completed NCT02531243 - Computer-Aided Learning for Managing Stress N/A
Completed NCT02733575 - Compassion Focused Therapy for Distressing Experiences N/A
Completed NCT02653729 - Cbt for Psychosis and Affect on Psychosis Symptoms Phase 2
Not yet recruiting NCT02244970 - Mindfulness RCT for Early Psychosis N/A
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Withdrawn NCT00786318 - Ziprasidone vs Standard Therapy for Agitated Patients in the ED Phase 4
Recruiting NCT00722163 - A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis Phase 0